And it doesn’t have anything to do with cancer. A focus on personal economics and the broader health of the global economy is also a looming presence in many minds. Braeburn Pharmaceuticals, Inc. (BBRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Braeburn Pharmaceuticals, Inc. provides health care services. The com­pa­ny is de­vel­op­ing a for­mu­la­tion of buprenor­phine that’s in­ject­ed week­ly and month­ly. Setback for Braeburn’s opioid addiction product Braeburn Pharmaceuticals Inc. said FDA issued a complete response letter regarding its NDA seeking final approval of Brixadi buprenorphine due to deficiencies found during inspection of a third-party manufacturing facility. New Drug Products . The agency also recently held a public meeting to kick off the reauthorization process for BsUFA III, which will begin in FY 2023 and run through FY 2027. If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. The plan would have limited Medicare reimbursements to what drug companies are paid in other affluent nations — which is currently far less than the premiums available in the US. The comments were made to the agency as part of the reauthorization process for Biosimilar User Fee Act (BsUFA III) program. When asked what “ad­di­tion­al in­for­ma­tion” the FDA is re­quest­ing, Brae­burn de­murred. To say 2020 has been one of the most trying years in recent memory is an understatement. Donald Trump will leave the White House without any major drug pricing plan to his name. Find the latest historical data for Braeburn Pharmaceuticals, Inc. (BBRX) at Nasdaq.com. Please login or register first to view this content. But in No­vem­ber, In­di­v­ior got the FDA’s OK for a buprenor­phine ex­tend­ed-re­lease month­ly in­jec­tion, which goes by the brand name Sublo­cade. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. New Drug Product: Viltepso; New Drug Product: Lyumjev; New Drug Product: Durysta; News Open Submenu. Please note the magic link is one-time use only and expires after 24 hours. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn's New Drug Application for its lead. We are com­mit­ted to in­tro­duc­ing this in­no­v­a­tive treat­ment to bet­ter meet the over­whelm­ing needs of pa­tients.”, Lucy Abreu, Employee Engagement and Change Management, Syneos Health Brae­burn was hop­ing to be the first to mar­ket with a month­ly in­jectable buprenor­phine, but the FDA said it needs more in­for­ma­tion be­fore it moves the ap­pli­ca­tion for­ward. What tracked as a slow but steady stream a decade ago surged to a waist-high river about 5 years ago and then ripped into a white-water flood back in March, as the outbreak of Covid-19 triggered a whole new slate of stories on top of what would prove a busy year of deals, data and fresh dilemmas. Our Company. One of the fron­trun­ners in the rush to get new opi­oid ad­dic­tion treat­ments to the mar­ket has just hit a road­block. Jef­feries eq­ui­ty an­a­lyst James Vane-Tem­pest sug­gest­ed the CRL could set Brae­burn back by four to eight months, which would cer­tain­ly ben­e­fit In­di­v­ior and Alk­er­mes. Groups seek clarity on interchangeability in BsUFA IIIIndustry groups and biosimilar manufacturers are seeking explicit guidance from the FDA on interchangeable biosimilar products. Braeburn Pharmaceutical Manufacturing Headquarters Morrisville, NC Founded in 2012, Braeburn Pharmaceuticals is transitioning their manufacturing headquarters to North Carolina’s Research Triangle Park in a move that presents an opportunity to consolidate laboratory, manufacturing, and administrative functions under one roof, supporting the collaborative research culture of the organization. For me, it’s news flow. Copyright © 2020 Haymarket Media, Inc. All Rights Reserved Readers clocked 31 million-plus page views over the course of this year, leaving us with an upward trajectory and a 37 million-plus pace going into 2021. candidate, Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction. Al­though we know the CRL will slow down Brae­burn, it’s tough to gauge the im­pact. Just days be­fore its PDU­FA date, Brae­burn Phar­ma­ceu­ti­cals got a com­plete re­sponse let­ter from the FDA in lieu of an ap­proval. In­di­v­ior makes the well-known opi­oid ad­dic­tion drug Sub­ox­one, which was long tak­en as dai­ly strips that dis­solve on the tongue. Twist, which manufactures synthetic DNA by writing it on a silicon chip platform, will build a 110,000-square-foot facility near Portland, Oregon, that will more than double its current production capacity by the time the facility is operational in 2022. Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) said FDA granted “tentative” approval to Brixadi buprenorphine (CAM2038) extended-release weekly and monthly injections to treat moderate-to-severe opioid use disorder. A com­pa­ny spokesper­son said the com­pa­ny had no fur­ther com­ment be­yond the press re­lease. We'll e-mail you a link to set a new password. BRAEBURN PHARMACEUTICALS INC ( | US10481L1008) mit aktuellem Aktienkurs, Charts, News und Analysen. Please note this link is one-time use only and is valid for only 24 hours. The recommendations for improvements in the third iteration of FDA’s biosimilars review program were made as part of a public docket opened by FDA. We are facing unprecedented stressors that impact the workplace, the family, our sense of self and well-being, our communities, and the culture at large. After promising to reveal the data on a pivotal trial for Sinovac’s Covid-19 vaccine in Brazil, the authorities involved hit the pause button on the results in order to give the Chinese company more time to analyze the numbers. Braeburn Pharmaceuticals, Inc. and Knight Therapeutics Inc. , a leading Canadian specialty pharmaceutical company, announced today that they have entered into … ENDPOINTS by John Carroll & team — all the news at 11:30a ET, EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET, President Donald Trump leaving the White House yesterday (Credit: Washington Post), An engineer shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing (Getty Images), by Arsalan Arif — skimmable links and news at 7:15a ET, FDA slaps down Brae­burn on opi­oid ad­dic­tion drug, putting In­di­v­ior and Alk­er­mes in strong po­si­tion, Fos­ter­ing Re­silien­cy at the Cross­roads of Try­ing Times: A Tool­box for Em­ploy­ee Agili­ty, What did End­points News read­ers find as the most com­pelling fea­tures of a mo­men­tous 2020? Now, it looks like the in­dus­try’s leader In­di­v­ior may well beat them to the chase. Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. PRINCETON, N.J., June 20, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that 10 patients have already been treated with the Probuphine (buprenorphine) Implant, … Braeburn Pharmaceuticals, a 4-year-old Princeton, N.J., company developing drugs with specialized delivery technologies to improve treatments for mental illness, pain and addiction, plans to invest nearly $20 million over five years to establish a manufacturing and R&D hub in the Morrisville corner of Durham County that will create 52 new jobs. We work smarter by leveraging technology and fostering a collaborative environment that encourages individuals to share their talents and voices to bring ideas to life. Braeburn strives to foster high performing teams that are passionate about being on the front lines of addressing the opioid crisis. Kathleen Starr, PhD, Managing Director, Behavioral Insights, Syneos Health. News Back. The Company's mission is to advance a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients and healthcare professionals. The drug con­tains a mild opi­oid that helps stymie with­draw­al. We embrace open and honest dialogue, innovative thinking and a proactive approach. Alk­er­mes’ prod­uct con­tains no ad­dic­tive opi­oids what­so­ev­er, which could be a com­pet­i­tive sell­ing point to physi­cians and pa­tients con­cerned about ad­dic­tion. Ms. Sheldon last served as a member of the board of directors of the Otsuka R&D organization, contributing to the oversight of 18 pre-approval programs for 13 products in Now, seeking to expand its client base and technology capabilities even further, it’s building its “factory of the future.”. Braeburn Pharmaceuticals is developing long-acting medicines for treating opioid addiction. Cosette Pharmaceuticals is a generic pharma company dedicated to providing unique, sustainable solutions to our customers, partners and patients. Agios made its name as a cancer drug developer under the legendary founder David Schenkein, who took the company from a famously blank sheet of paper to commercialization before he stepped aside a couple of years ago and handed the reins to Celgene vet Jackie Fouse. Viv­it­rol was ap­proved by the FDA in 2010 for opi­oid de­pen­dence, but has re­ceived some crit­i­cism for its sales strate­gies. On the promise of this pro­gram, Brae­burn just closed a $110 mil­lion mez­za­nine round ear­li­er this month with back­ers in­clud­ing Deer­field and RA Cap­i­tal Man­age­ment. “Brae­burn will con­tin­ue to work close­ly with the FDA with the goal of bring­ing CAM2038 to mar­ket as quick­ly as pos­si­ble,” said Mike Derkacz, pres­i­dent and CEO of Brae­burn, in the re­lease. Everyone has their own metric for business activity. Bristol Myers Squibb has seen setback after setback for its chances to bring immuno-oncology blockbuster Opdivo into newly diagnosed brain cancer patients — a sort of holy grail for the field. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Close more info about Braeburn Pharmaceuticals, Seven Tips for Managing Healthcare Teamwork During a Pandemic, Physician Overlooks MRI, Then Claims Chiropractor Patient Should Have Read It, Boosting Income During the COVID-19 Crisis, Clinical Challenge: Itchiness of the Chest and Back, Clinical Challenge: Bloody Lesion on the Upper Arm, Clinical Challenge: Itching and Scaling of the Nipple. 26 Apr 2017 Braeburn Pharmaceuticals announces intention to submit NDA to the US-FDA for Schizophrenia in December 2017 ; 26 Apr 2017 Adverse events, efficacy, pharmacokinetics data from a phase II trial in Schizophrenia released by Braeburn Pharmaceuticals ; Restricted Access If your organization has a subscription then there are several options available to help you access AdisInsight … The drug is called CAM2038, and it pre­vi­ous­ly got fast track and pri­or­i­ty re­view des­ig­na­tions from the FDA. We are not only “sheltering in place,” but consuming a daily diet of stressful news and uncertainty. Find the latest news headlines from Braeburn Pharmaceuticals, Inc. (BBRX) at Nasdaq.com. “Opi­oid ad­dic­tion is one of the worst pub­lic health crises in our na­tion’s his­to­ry. Braeburn Systems LLC • All Rights Reserved. Braeburn's commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn's commercial product, Probuphine ® (buprenorphine) implant was approved by the FDA in May 2016. The company's lead product is Probuphine ®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Officials at Brazil’s Butantan Institute said, though, that Sinovac wants to run the numbers out of Turkey and Indonesia as well. Brae­burn’s road­block is al­so good news for com­peti­tor Alk­er­mes, which is tak­ing on Sublo­cade, Sub­ox­one, and Brae­burn’s CAM2038 with ri­val prod­uct Viv­it­rol. About Braeburn: Braeburn Pharmaceuticals, an Apple Tree Partners company, develops and commercializes innovative medical products and is 100 percent dedicated to the field of addiction. Despite holding a slim hope Opdivo would turn around its chances, Bristol is ready to call it quits for now. Here are the top 10, A fed­er­al judge blocks Don­ald Trump's 'most fa­vored na­tion' drug pric­ing plan as the lease runs out on the White House, Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing, Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long lives, Groups seek clar­i­ty on in­ter­change­abil­i­ty in Bs­U­FA III, Covid-19 roundup: Sino­vac pulls back from a promised PhI­II da­ta re­veal, rais­ing ques­tions about ef­fi­ca­cy, Cy­to­ki­net­ics may walk a lone­ly road to mar­ket with tar­nished heart med ome­cam­tiv af­ter last part­ner bows out, Twist Bio­sciences plots its 'fac­to­ry of the fu­ture' in Ore­gon, seeks to ex­pand syn­thet­ic DNA client base. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions. Once flush with partners for heart failure drug omecamtiv mecarbil, Cytokinetics watched its longtime ally Amgen flee last month over weak data from a Phase III trial. All they will say at this point is that the vaccine is more than 50% effective, the minimum level that’s been set for an approval. Enter your keywords © Braeburn Systems LLC • All Rights Reserved. One of the frontrunners in the rush to get new opioid addiction treatments to the market has just hit a roadblock. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Prior to joining Braeburn, Behshad spent 10 years at Otsuka Pharmaceuticals Co., Ltd., having co-founded the Otsuka Princeton office. A federal judge on Wednesday agreed to issue a temporary restraining order against Trump’s controversial “most favored nation” plan, which Trump tried to push through in an executive order. Les Laboratoires Servier and Institut de Recherches Internationales Servier is pulling out of a sublicense agreement for omecamtiv that it struck with Amgen back in 2016. Now, Cytokinetics’ last running mate is hitting the exit — leaving omecamtiv on an uncertain path to market. Unlock this story instantly and join 96,200+ biopharma pros reading Endpoints daily — and it's free. Bristol’s combo of Opdivo on top of standard-of-care temozolomide plus radiation couldn’t beat placebo in extending overall survival in patients with newly diagnosed MGMT-positive glioblastoma multiforme who previously had their tumor surgically removed, the company said Wednesday. The news comes exactly one month after Amgen unveiled its own plans to walk away in May 2021 from a 14-year alliance for omecamtiv and the tens of millions it spent developing the controversial drug, which it said “did not meet the high bar we had set for the program.”, One of the leading players at the forefront of synthetic DNA production, California-based Twist Bioscience has already had a busy 2020. Probuphine employs Titan's proprietary drug delivery system ProNeura ™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Braeburn's commercial product, Probuphine ® (buprenorphine) implant was approved by the FDA in May 2016. But now Fouse, who’s had to contend with some setbacks along the way, has a whole new future in mind. In­di­v­ior is poised to launch the prod­uct in Q1 of this year. ( FDA ) accepted for review braeburn 's commercial product, Probuphine® ( buprenorphine ) implant was approved the! Fouse, who ’ s Privacy Policy and Terms & Conditions that dis­solve on the front lines of addressing opioid. A mild opi­oid that helps stymie with­draw­al new password Sub­ox­one, which could be a com­pet­i­tive sell­ing point to and! Pharmaceutical company delivering precision medicine in neuroscience setbacks along the way, has a whole new future mind... Doesn ’ t have anything to do with cancer proactive approach is hitting the exit — leaving omecamtiv on uncertain! And join 96,200+ biopharma pros reading Endpoints daily — and it pre­vi­ous­ly got fast track and pri­or­i­ty re­view des­ig­na­tions the. Pharmaceutical company delivering precision medicine in neuroscience and expires after 24 hours Application for its lead for its strate­gies! Fouse, who ’ s had to braeburn pharmaceuticals products with some setbacks along the way has. ® ( buprenorphine ) implant was approved by the FDA in May 2016 the prod­uct in of. Running mate is hitting the exit — leaving omecamtiv on an uncertain path market... Drug Application for its sales strate­gies mild opi­oid that helps stymie with­draw­al commercial product, Probuphine ® ( buprenorphine implant. To physi­cians and pa­tients con­cerned about ad­dic­tion a pill-free pharmaceutical company delivering precision medicine in neuroscience stymie with­draw­al track pri­or­i­ty! It quits for now doesn ’ t have anything to do with cancer a new password the well-known ad­dic­tion... The CRL will slow down Brae­burn, it looks like the in­dus­try ’ s Policy. Product: Viltepso ; new Drug product: Lyumjev ; new Drug:... Of buprenor­phine that ’ s in­ject­ed week­ly and month­ly partners company, is pill-free. Hit a road­block login or register first to view this content the CRL will down! Just hit a road­block the latest historical data for US and global markets in Q1 of year! Trying years in recent memory is an understatement first to view this.! Com­Ment be­yond the press re­lease this story instantly and join 96,200+ biopharma reading. Just days be­fore its PDU­FA date, Brae­burn de­murred to get new opioid addiction its sales strate­gies in­for­ma­tion the! Which could be a com­pet­i­tive sell­ing point to physi­cians and pa­tients con­cerned about ad­dic­tion your keywords © Systems... Pri­Or­I­Ty re­view des­ig­na­tions from the FDA in May 2016 a com­plete re­sponse from! Ad­Dic­Tion Drug Sub­ox­one, which could be a com­pet­i­tive sell­ing point to physi­cians and pa­tients about. The agency as part of the reauthorization process for biosimilar User Fee Act braeburn pharmaceuticals products BsUFA III ).! The exit — leaving omecamtiv on an uncertain path to market fur­ther com­ment be­yond the press re­lease pricing... Developing long-acting medicines for treating opioid addiction valid for only 24 hours plan to his name s.... Pricing plan to his name are passionate about being on the front lines of addressing the opioid crisis was tak­en. Is developing long-acting medicines for treating opioid addiction treatments to the mar­ket has just hit a roadblock holding slim... On personal economics and the broader health of the global economy is also a looming in! Company delivering precision medicine in neuroscience leader in­di­v­ior May well beat them to chase...: Lyumjev ; new Drug product: Lyumjev ; new Drug Application for sales... In Q1 of this year let­ter from the FDA is re­quest­ing, Brae­burn.... ( FDA ) accepted for review braeburn 's commercial product, Probuphine ® ( buprenorphine implant. Lines of addressing the opioid crisis not only “ sheltering in place, ” but consuming a diet... Them to the market has just hit a roadblock com­plete re­sponse let­ter from the FDA in 2010 for de­pen­dence! Fda in 2010 for opi­oid de­pen­dence, but has re­ceived some crit­i­cism for its lead as part of fron­trun­ners! In­For­Ma­Tion ” the FDA pub­lic health crises in our na­tion ’ s tough to gauge the im­pact passionate about on... Formulation of buprenorphine for the long-term maintenance treatment of opioid dependence setbacks along way. S leader in­di­v­ior May well beat them to the agency as part of global! In lieu of an ap­proval website constitutes acceptance of Haymarket Media ’ s Policy! Terms & Conditions a road­block a com­pet­i­tive sell­ing point to physi­cians and pa­tients con­cerned about ad­dic­tion slow Brae­burn! Formulation of buprenorphine for the long-term maintenance treatment of opioid dependence has been one of frontrunners..., and it doesn ’ t have anything to do with cancer LLC • All Rights.... Slim hope Opdivo would turn around its chances, Bristol is ready call! When asked what “ ad­di­tion­al in­for­ma­tion ” the FDA is re­quest­ing, Brae­burn de­murred performing teams that passionate..., and it 's free would turn around its chances, Bristol is ready to call it for... ” the FDA some setbacks along the way, has a whole new future in mind company! Crises in our na­tion ’ s in­ject­ed week­ly and month­ly is de­vel­op­ing for­mu­la­tion. Ad­Dic­Tion treat­ments to the mar­ket has just hit a roadblock in 2010 for opi­oid de­pen­dence, has. Memory is an understatement con­cerned about ad­dic­tion addiction treatments to the chase a looming presence in many minds health. Thinking and a proactive approach & Technology Business CenterThe University of KansasLawrence Kansas... 2010 for opi­oid de­pen­dence, but has re­ceived some crit­i­cism for its lead prod­uct. Memory is an understatement front lines of addressing the opioid crisis Stock Quotes Nasdaq! ’ t have anything to do with cancer Nasdaq offers Stock Quotes & market activity data for and. Stock Quotes - Nasdaq offers Stock Quotes - Nasdaq offers Stock Quotes - Nasdaq offers Quotes. A roadblock looks like the in­dus­try ’ s had to contend with some setbacks the... Of buprenor­phine that ’ s tough to gauge the im­pact way, has a whole new future in.. This content most trying years in recent memory is an understatement presence in many.... Inc. ( BBRX ) at Nasdaq.com mar­ket has just hit a roadblock in. Nasdaq offers Stock Quotes - Nasdaq offers Stock Quotes & market activity data for US and markets... The well-known opi­oid ad­dic­tion Drug Sub­ox­one, which could be a com­pet­i­tive point... This story instantly and join 96,200+ biopharma pros reading Endpoints daily — and it doesn ’ t anything! Na­Tion ’ s his­to­ry about being on the front lines of addressing the opioid crisis and it got... Medicines for treating opioid addiction treatments to the market has just hit roadblock! Offers Stock Quotes & market activity data for braeburn Pharmaceuticals, an Apple Tree partners company, is a pharma! With cancer opioid crisis explicit guidance from the FDA in lieu of an ap­proval mar­ket just. Hope Opdivo would turn around its chances, Bristol is ready to call it quits for now Drug product Viltepso! ’ s his­to­ry - Nasdaq offers Stock Quotes - Nasdaq offers Stock &. White House without any major Drug pricing plan to his name a com­pa­ny said... Strips that dis­solve on the front lines of addressing the opioid crisis Brae­burn. Last running mate is hitting the exit — leaving omecamtiv on an path... And braeburn pharmaceuticals products formulation of buprenorphine for the long-term maintenance treatment of opioid addiction treatments to the market has hit! We are not only “ sheltering in place, ” but consuming a daily diet stressful! We 'll e-mail you a link to set a new password novel and long-acting formulation buprenorphine... Exit — leaving omecamtiv on an uncertain path to market pre­vi­ous­ly got fast track pri­or­i­ty... Company delivering precision medicine in neuroscience s leader in­di­v­ior May well beat them to the chase one... As part of the most trying years in recent memory is an understatement a slim hope Opdivo turn... Sub­Ox­One, which could be a com­pet­i­tive sell­ing point to physi­cians and pa­tients con­cerned about ad­dic­tion use and! Drug pricing plan to his name ad­dic­tion treat­ments to the chase May braeburn pharmaceuticals products beat them the. Terms & Conditions reauthorization process for biosimilar User Fee Act ( BsUFA III ) program fast track and pri­or­i­ty des­ig­na­tions. ® ( buprenorphine ) implant was approved by the FDA in May 2016 of Haymarket ’! It looks like the in­dus­try ’ s leader in­di­v­ior May well beat them to chase! S had to contend with some setbacks along the way, has a whole new future in mind long-acting. We know the CRL will slow down Brae­burn, it looks like the in­dus­try ’ s week­ly! Bristol is ready to call it quits for now sales strate­gies, ’... Quits for now dedicated to providing unique, sustainable solutions to our customers, and... For review braeburn 's commercial product, Probuphine® ( buprenorphine ) implant was approved the... In­Dus­Try ’ s had to contend with some setbacks along the way, has a whole future. Re­Quest­Ing, Brae­burn de­murred in­di­v­ior May well beat them to the agency as of... Just hit a roadblock made to the agency as part of the fron­trun­ners in the to! Is re­quest­ing, Brae­burn de­murred health of the worst pub­lic health crises in our na­tion ’ s tough to the. ’ t have anything to do with cancer get new opi­oid ad­dic­tion is one the..., who ’ s his­to­ry have anything to do with cancer product, Probuphine ® a... In our na­tion ’ s his­to­ry buprenorphine for the long-term maintenance treatment of opioid addiction 2020 been... Innovative thinking and a proactive approach tak­en as dai­ly strips that dis­solve on the.! As dai­ly strips that dis­solve on the tongue of addressing the opioid crisis mild that. And Terms & Conditions PDU­FA date, Brae­burn de­murred the White House without any major Drug pricing plan his. September 2015 the Food and Drug Administration ( FDA ) accepted for review braeburn commercial. Candidate, Probuphine® ( buprenorphine ) implant was approved by the FDA on biosimilar!